Soligenix, Inc. issued a corporate update letter on July 8, 2025, from President and CEO Dr. Christopher J. Schaber, outlining key highlights and upcoming milestones. The letter reaffirmed the anticipation of top-line results for the HyBryte™ FLASH2 study in the second half of 2026, and for SGX945 in Behçet's disease and SGX302 in psoriasis in the third quarter of 2025.
The company provided market potential estimates, projecting peak annual net sales of HyBryte™ in the U.S. to exceed $90 million, with the total worldwide CTCL market estimated at over $250 million annually. The total addressable worldwide psoriasis market for SGX302 is estimated to exceed $1 billion annually, and the SGX945 market in Behçet's Disease is estimated at approximately $200 million annually.
Dr. Schaber also addressed the company's financial position, stating that current financing strategies provide sufficient capital and cash runway into the first quarter of 2026. The company continues to evaluate strategic options, including partnerships and merger and acquisition opportunities, to advance its late-stage pipeline and achieve significant commercial returns.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.